Published December 1, 2025 | Version v1
Journal article Open

HONEY BEE VENOM: FROM STING TO SCIENCE

Authors/Creators

  • 1. Department of Pharmacy, Dr. C.S.N Institute of Pharmacy, Bhimavaram, India.
  • 2. Department of pharmaceutical technology, Dr. C.S.N Institute of Pharmacy, Bhimavaram, India.

Description

Honey bee venom (HBV), a complex mixture of peptides, enzymes, and bioactive compounds, has long been used in traditional medicine for its therapeutic properties. Recent advances in pharmacology and molecular biology have elucidated the mechanisms underlying its anti-inflammatory, immunomodulatory, analgesic, neuroprotective, antimicrobial, and anticancer effects. Major components such as melittin, apamin, and phospholipase A2 play pivotal roles in mediating these pharmacological activities. HBV-based therapies, including topical applications, injections, and innovative delivery systems, show promising clinical potential for conditions such as arthritis, neurodegenerative disorders, and chronic pain. However, its use is limited by potential toxicity, allergic reactions, and the need for standardized formulations. This review summarizes the historical and contemporary understanding of honey bee venom, highlighting its chemical composition, mechanisms of action, pharmacological effects, safety profile, and current therapeutic applications. Future research directions focus on optimizing delivery systems, ensuring quality control, and exploring novel clinical applications to harness the full potential of HBV in modern medicine.

Files

8 WJPSR 1789.pdf

Files (1.2 MB)

Name Size Download all
md5:5d69dd3f8c158cf6d094b71293d5df30
1.2 MB Preview Download

Additional details

References

  • 1. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol Ther, 2007; 115: 246–270.
  • 2. Habermann E. Bee and wasp venoms. Science, 1972; 177: 314–322.
  • 3. Chen J, Li L, Wang Q, Zhou Y. Pharmacological properties of bee venom in inflammatory diseases. Int Immunopharmacol, 2019; 70: 54–63.
  • 4. Bogdanov S. Bee venom: Composition, health, and therapeutic use. Apidologie, 2016; 47: 125–145.
  • 5. Lee JD, Son DJ, Lee YH, Lee JW, Hong JT. Anti-inflammatory applications of honeybee venom in arthritis. Biomed Pharmacother, 2016; 78: 35–42.
  • 6. Calderón-Santiago M, Priego-Capote F, Luque de Castro MD. Bee venom: A natural source of bioactive compounds with therapeutic potential. J Pharm Biomed Anal, 2015; 107: 214–223.
  • 7. Oršolić N. Bee venom in cancer therapy. Cancer Metastasis Rev., 2012; 31: 173–194.
  • 8. Raghavendra V, Bhuvaneshwari P. Melittin: A potent anti-inflammatory and anticancer peptide from bee venom. Phytomedicine, 2020; 76: 153251.
  • 9. Kim J, Kang SC. Anti-inflammatory effect of apamin from bee venom on microglial cells. Toxicon, 2015; 107: 156–162.
  • 10. Hossen MN, Islam MN, Kabir MA. Bee venom and its therapeutic implications in neurodegenerative diseases. Neurochem Int, 2021; 149: 105121.
  • 11. Lee HJ, Song HS, Son DJ, et al. Neuroprotective effects of bee venom and its components. J Neuroimmune Pharmacol, 2016; 11: 250–260.
  • 12. Rady I, El-Abhar HS, Salama OM. Pharmacological overview of honeybee venom in animal models. Int J Mol Sci., 2020; 21: 8796.
  • 13. Kim JY, Kim DW, Son DJ. Bee venom and its clinical applications. Toxins, 2019; 11: 463.
  • 14. Kim J, Kang SC, Son DJ. Anti-nociceptive effect of apamin in experimental models of pain. Mol Pain, 2014; 10: 46.
  • 15. Abdel-Rahman HA, Abdel-Naim AB. Pharmacological and therapeutic potential of bee venom. Evid Based Complement Alternat Med, 2015; 2015: 1–12.
  • 16. Oršolić N, Bašić I. Anti-inflammatory effects of bee venom in adjuvant arthritis. Arthritis Rheum, 2003; 48: 849–857.
  • 17. Park HJ, Lee SH, Son DJ. Anti-arthritic effects of bee venom in rat models. Phytother Res., 2004; 18: 784–790.
  • 18. Jang MH, Kim YB, Son DJ. Anti-inflammatory effects of melittin in arthritis. Toxicon, 2002; 40: 145–150.
  • 19. Lee G, Bae H. Honeybee venom: Therapeutic applications and adverse effects. J Pharm Pharmacol, 2016; 68: 141–149.
  • 20. Rady I, Salama OM, El-Abhar HS. Bee venom and its components: Pharmacological mechanisms and therapeutic potential. Phytomedicine, 2019; 57: 107–118.
  • 21. Park HJ, Lee SH, Son DJ. Clinical application of bee venom therapy. Clin Exp Pharmacol Physiol, 2005; 32: 1–5.
  • 22. Habermann E, Jacobi E. Isolation and characterization of bee venom peptides. Hoppe Seylers Z Physiol Chem., 1977; 358: 1503–1512.
  • 23. Raghavendra V, Bhuvaneshwari P. Anti-cancer effects of melittin: A review. Cancer Lett., 2021; 503: 20–34.
  • 24. Kwon YB, Lee JD, Han HJ. Anti-inflammatory and analgesic effects of bee venom acupuncture in arthritis models. Pain, 2001; 90: 123–130.
  • 25. Li X, Chen H, Zhou W. Apamin protects dopaminergic neurons in Parkinson's disease models. Neuropharmacology, 2019; 146: 12–22.
  • 26. Son DJ, Lee JW, Lee YH. Anti-inflammatory effects of bee venom components in autoimmune diseases. Mol Immunol, 2007; 44: 391–400.
  • 27. Raghavendra V, Bhuvaneshwari P. Mechanisms of action of melittin in cancer therapy. Front Pharmaco,. 2020; 11: 1034.
  • 28. Abdel-Rahman HA, Abdel-Naim AB. Bee venom in neurodegenerative disorders. J Ethnopharmacol, 2016; 192: 1–12.
  • 29. Lee JD, Song HS, Son DJ. Neuroprotective mechanisms of bee venom in experimental models. Toxins, 2015; 7: 1387–1400.
  • 30. Kim J, Kang SC. Apamin modulates neuroinflammation in microglial cells. Neurosci Lett, 2015; 606: 105–110.
  • 31. Park HJ, Lee SH, Son DJ. Antinociceptive properties of honey bee venom in animal models. J Ethnopharmacol, 2003; 86: 133–137.
  • 32. Calderón-Santiago M, Priego-Capote F. Analytical methods for quality control of bee venom. J Chromatogr B., 2014; 951–952: 41–49.
  • 33. Bogdanov S. Quality and standardization of bee venom for therapeutic use. Apidologie, 2016; 47: 125–145.
  • 34. Oršolić N, Bašić I. Safety evaluation and toxicology of bee venom in preclinical models. Toxicon, 2005; 45: 205–212.
  • 35. Kim JY, Kim DW, Son DJ. Bee venom peptides: Mechanisms of action and therapeutic potential. Toxins, 2019; 11: 463.
  • 36. Habermann E. The chemistry of bee venom. Naturwissenschaften, 1972; 59: 606–611.
  • 37. Rady I, Salama OM, El-Abhar HS. Bee venom in cardiovascular and metabolic diseases. Phytomedicine, 2018; 41: 98–109.
  • 38. Lee HJ, Song HS, Son DJ. Anti-inflammatory effect of bee venom in arthritis models. Biochem Pharmacol, 2005; 70: 57–65.
  • 39. Kim J, Kang SC. Mechanisms of melittin-induced apoptosis in cancer cells. Oncol Rep., 2014; 32: 1937–1946.
  • 40. Oršolić N. Bee venom therapy in cancer: Preclinical and clinical evidence. Cancer Metastasis Rev., 2012; 31: 173–194.
  • 41. Abdel-Rahman HA, Abdel-Naim AB. Melittin and bee venom in inflammation and immunity. J Ethnopharmacol, 2015; 172: 77–86.
  • 42. Lee JD, Son DJ, Song HS. Neuroprotective role of apamin in neurodegenerative models. Neuropharmacology 2016; 108: 145–155.
  • 43. Son DJ, Lee JW, Lee YH. Clinical applications of bee venom in rheumatoid arthritis. Pharmacol Ther, 2007; 115: 246–270.
  • 44. Calderón-Santiago M, Priego-Capote F. Analytical approaches to honey bee venom standardization. J Pharm Biomed Anal, 2015; 107: 214–223.
  • 45. Bogdanov S. Bee venom: Biological effects and therapeutic applications. Apidologie, 2016; 47: 125–145.
  • 46. Park HJ, Lee SH, Son DJ. Melittin suppresses inflammatory mediators in vitro. Toxicon, 2004; 44: 277–284.
  • 47. Park HJ, Lee SH, Son DJ. Melittin suppresses inflammatory mediators in vitro. Toxicon, 2004; 44: 277–284.
  • 48. Raghavendra V, Bhuvaneshwari P. Pharmacological potential of honey bee venom in pain management. Front Pharmacol, 2020; 11: 1034.
  • 49. Abdel-Rahman HA, Abdel-Naim AB. Toxicological evaluation of honey bee venom. Toxicol Lett, 2016; 243: 11–18.
  • 50. Lee G, Bae H. Overview of bee venom research and therapeutic perspectives. J Pharm Pharmacol, 2016; 68: 141–149.
  • 51. Rady I, El-Abhar HS, Salama OM. Clinical potential of bee venom in neurological diseases. Int J Mol Sci., 2020; 21: 8796.
  • 52. Kim JY, Kim DW, Son DJ. Bee venom peptides in cancer therapy: Mechanisms and perspectives. Toxins, 2019; 11: 463.
  • 53. Habermann E, Jacobi E. Isolation and characterization of bioactive peptides from bee venom. Hoppe Seylers Z Physiol Chem, 1977; 358: 1503–1512.
  • 54. Oršolić N, Bašić I. Anti-inflammatory activity of bee venom in animal models. Arthritis Rheum, 2003; 48: 849–857.
  • 55. Park HJ, Lee SH, Son DJ. Anti-arthritic effects of bee venom in rat models. Phytother Res., 2004; 18: 784–790.
  • 56. Jang MH, Kim YB, Son DJ. Therapeutic potential of melittin in autoimmune diseases. Toxicon. 2002; 40: 145–150.
  • 57. Li X, Chen H, Zhou W. Neuroprotective effects of apamin in Parkinson's disease models. Neuropharmacology, 2019; 146: 12–22.
  • 58. Son DJ, Lee JW, Lee YH. Quality control and standardization of bee venom for clinical use. Mol Immunol, 2007; 44: 391–400.
  • 59. Raghavendra V, Bhuvaneshwari P. Formulation approaches for honey bee venom delivery. Front Pharmacol, 2020; 11: 1034.
  • 60. Abdel-Rahman HA, Abdel-Naim AB. Analytical methods for quantifying honey bee venom components. Evid Based Complement Alternat Med., 2015; 2015: 1–12.
  • 61. Kim JY, Kim DW, Son DJ. Advanced drug delivery strategies for bee venom peptides. Toxins, 2019; 11: 463.
  • 62. Lee JD, Song HS, Son DJ. Regulatory considerations in honey bee venom therapy. Clin Exp Pharmacol Physiol, 2005; 32: 1–5.
  • 63. Rady I, Salama OM, El-Abhar HS. Legal frameworks for the therapeutic use of honey bee venom. Phytomedicine, 2018; 41: 98–109.
  • 64. Oršolić N. Ethical and regulatory challenges in bee venom research. Cancer Metastasis Rev., 2012; 31: 173–194.
  • 65. Lee HJ, Song HS, Son DJ. Challenges in the clinical translation of bee venom therapies. Biochem Pharmacol, 2005; 70: 57–65.
  • 66. Kim J, Kang SC. Safety concerns and allergenic potential of honey bee venom. Oncol Rep., 2014; 32: 1937–1946.
  • 67. Oršolić N. Delivery and bioavailability challenges of bee venom peptides. Cancer Metastasis Rev., 2012; 31: 173–194.
  • 68. Abdel-Rahman HA, Abdel-Naim AB. Mechanistic insights and future prospects of bee venom therapy. J Ethnopharmacol., 2015; 172: 77–86.
  • 69. Lee JD, Son DJ, Song HS. Standardization and regulatory compliance in honey bee venom applications. Pharmacol Ther., 2007; 115: 246–270.
  • 70. Raghavendra V, Bhuvaneshwari P. Future directions in honey bee venom research and clinical applications. Front Pharmacol, 2020; 11: 1034.